InvestorsHub Logo
Followers 38
Posts 5557
Boards Moderated 0
Alias Born 02/25/2011

Re: Sam81 post# 64247

Tuesday, 11/10/2015 5:03:55 AM

Tuesday, November 10, 2015 5:03:55 AM

Post# of 425933
Sam, R-I " risk" is reducing significantly, not just as interim takes longer, but as Suntrust suggests, AMRN passed an inflection point and bias is now higher PT as we approach interim with greater confidence of efficacy from a multitude of positive effects (Cherry + other pleiotropic effects ) that improve not ONLY CVD - but overall health.

Lastly, another benefit of a full trial run is showing reduction in hard mace (vs. angina ) and the reduction in all cause mortality.

We've got a winner in EPA gents...

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News